ClinicalTrials.gg
CompletedNCT00093145Updated Nov 25, 2019Results posted

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

A Phase 2 interventional study of Albumin-bound paclitaxel and Carboplatin in Breast Cancer, sponsored by Celgene. Completed at 14 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2004, registered Oct 2004).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.

Enrollment
75th of 108
32 · median 60
Started
2004
the only one that year
Phase 2
67 of 108
9 open now
Registered
3rd of 108
by date
Lead sponsor
9 of 108
Celgene

Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 75th largest by enrollment, is the only one that started in 2004, is one of 67 in phase 2, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Advanced Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed adenocarcinoma of the breast
  • Tumor shows 3+ overexpression of the human epidermal growth factor receptor 2 ()/proto-oncogene by immunohistochemistry assay, or is fluorescence in situ hybridization (FISH)+
  • Stage IV disease
  • At least 3 weeks since prior cytotoxic chemotherapy
  • At least 4 weeks since radiotherapy with full recovery
  • At least 4 weeks since major surgery with full recovery
  • (ECOG) performance status 0-2
  • At least 18 years old
  • (ANC) at least 1.5 x 10\^9 cells/L
  • at least 100 x 10\^9 cells/L
  • at least 9 g/dL
  • Aspartame aminotransferase (), alanine aminotransferase (ALT) less than 2.5X upper limit normal
  • Alkaline Phosphatase less than 1.5X upper limit normal
  • Creatinine less than 1.5 gm/dL
  • Normal
  • Negative pregnancy test
  • Agree to use method to avoid pregnancy
  • is obtained

Exclusion criteria

Exclusion Criteria:

  • Up to one regimen of prior or adjuvant chemotherapy is allowed. One year since Taxane and Herceptin treatment.
  • Cumulative life-time dose of doxorubicin is greater than 360 mg/m\^2
  • Concurrent immunotherapy or hormonal therapy
  • Parenchymal , if present, must be documented to be clinically and radiographically stable for at least 6 months after treatment
  • Serious intercurrent medical or psychiatric illness, including serious active infection
  • History of congestive heart failure
  • History of other within the last 5 years which could affect the diagnosis or assessment of breast cancer
  • Patients who have received an drug within the previous 3 weeks
  • Patient is currently enrolled in another clinical study receiving investigational therapies
  • Pregnant or nursing women
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Albumin-bound paclitaxel, Carboplatin + Herceptin

    Participants received albumin-bound paclitaxel, 100 mg/m\^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.

    Drug: Albumin-bound paclitaxel · Drug: Carboplatin · Drug: Herceptin®

Interventions

  • Administered by intravenous infusion.

    Also known as: ABI-007, ABRAXANE®

  • Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.

    Also known as: Paraplatin®

  • Administered by IV infusion

    Also known as: Trastuzumab

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response

    Percentage of participants who achieved an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. A partial response (PR) is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing, or with the persistence of one or more non-target lesions and/or the maintenance of tumor marker level above the normal limits.

    Time frame: Objective response was evaluated every 2 cycles, up to a maximum of 39 cycles (approximately 39 months)

Secondary outcomes

  1. Percentage of Participants With a Total Response

    Total response was defined as the percentage of participants with stable disease (SD) for ≥ 16 weeks or complete or partial overall response. Stable disease was defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. Progressive disease is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: Evaluated every 2 cycles, up to a maximum of 39 cycles.

  2. Time to Disease Progression

    Time to disease progression was measured from the date of first dose of study drug to the start of disease progression. Patients who did not have disease progression at the end of follow-up were censored at the last known time that the patient was evaluated for progression. Progression is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Time to disease progression was summarized using Kaplan-Meier methods.

    Time frame: Assessed every 2 cycles, up to a maximum of 39 cycles.

  3. Duration of Response

    Duration of response was evaluated by measuring progression-free survival for participants with a complete response or partial response. Progression-free survival was defined as the time from the first dose of study drug to the start of progression or patient death (whichever occurred first). Participants who did not have progression or were still alive were censored at the last known time the patient was progression free. Patients that initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progression is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

    Time frame: Assessed every 2 cycles, up to a maximum of 39 cycles.

  4. Overall Patient Survival

    Overall survival was defined as the time from the day of randomization to patient death (due to any cause), as assessed by post study follow-up on a monthly basis for 3 months and every 3 months. Participants still alive were censored at the last known time that the patient was alive. Patient survival was estimated using Kaplan-Meier methods.

    Time frame: From Day 1 until approximately 44 months.

  5. Number of Participants With Adverse Events (AEs)

    A Treatment-emergent AE was any AE that began or worsened after the start of study drug through 30 days after the last dose of study drug or end of study whichever is later. A treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above

    Time frame: Day 1 up to 39 cycles

07

Results

Posted Jul 17, 2013

Participant flow

Due to slow patient accrual, only 32 patients of the planned 50 patients were enrolled. Patients were enrolled between June 2004 and July 2007.

Participant flow — Overall Study
MilestoneAlbumin-bound Paclitaxel, Carboplatin + Herceptin
Started32
At least one response assessment31
Completed15
Not completed17
Withdrew: Unacceptable toxicity only2
Withdrew: Physician decision5
Withdrew: Withdrawal by subject9
Withdrew: Other1

Outcome measures

PrimaryPercentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response

Percentage of participants who achieved an objective confirmed complete or partial overall response based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. A complete response (CR) is the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. A partial response (PR) is at least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing, or with the persistence of one or more non-target lesions and/or the maintenance of tumor marker level above the normal limits.

Time frame:
Objective response was evaluated every 2 cycles, up to a maximum of 39 cycles (approximately 39 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response
Percentage of participantsAlbumin-bound Paclitaxel, Carboplatin + Herceptin
Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response62.5 (45.7 to 79.3)
SecondaryPercentage of Participants With a Total Response

Total response was defined as the percentage of participants with stable disease (SD) for ≥ 16 weeks or complete or partial overall response. Stable disease was defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. Progressive disease is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
Evaluated every 2 cycles, up to a maximum of 39 cycles.
Reported as:
Number · percentage of participants
Percentage of Participants With a Total Response
percentage of participantsAlbumin-bound Paclitaxel, Carboplatin + Herceptin
Percentage of Participants With a Total Response81.3 (67.7 to 94.8)
SecondaryTime to Disease Progression

Time to disease progression was measured from the date of first dose of study drug to the start of disease progression. Patients who did not have disease progression at the end of follow-up were censored at the last known time that the patient was evaluated for progression. Progression is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Time to disease progression was summarized using Kaplan-Meier methods.

Time frame:
Assessed every 2 cycles, up to a maximum of 39 cycles.
Reported as:
Median · months
Time to Disease Progression
monthsAlbumin-bound Paclitaxel, Carboplatin + Herceptin
Time to Disease Progression16.6 (7.5 to 26.5)
SecondaryDuration of Response

Duration of response was evaluated by measuring progression-free survival for participants with a complete response or partial response. Progression-free survival was defined as the time from the first dose of study drug to the start of progression or patient death (whichever occurred first). Participants who did not have progression or were still alive were censored at the last known time the patient was progression free. Patients that initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progression is at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.

Time frame:
Assessed every 2 cycles, up to a maximum of 39 cycles.
Reported as:
Median · months
Duration of Response
monthsAlbumin-bound Paclitaxel, Carboplatin + Herceptin
Duration of Response17.8 (15.9 to 37.0)
SecondaryOverall Patient Survival

Overall survival was defined as the time from the day of randomization to patient death (due to any cause), as assessed by post study follow-up on a monthly basis for 3 months and every 3 months. Participants still alive were censored at the last known time that the patient was alive. Patient survival was estimated using Kaplan-Meier methods.

Time frame:
From Day 1 until approximately 44 months.
Reported as:
Median · months
Overall Patient Survival
monthsAlbumin-bound Paclitaxel, Carboplatin + Herceptin
Overall Patient SurvivalNA (NA to NA)
SecondaryNumber of Participants With Adverse Events (AEs)

A Treatment-emergent AE was any AE that began or worsened after the start of study drug through 30 days after the last dose of study drug or end of study whichever is later. A treatment related toxicity was one considered by the investigator to be possibly, probably or definitely related to study drug. AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on the following scale: Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, Grade 5 = death. A serious adverse event (SAE) is any untoward medical occurrence at any dose that: is fatal or life-threatening; results in persistent or significant disability or incapacity; requires or prolongs in-patient hospitalization; is a congenital anomaly/birth defect in the offspring of a patient; and conditions not included in the above that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above

Time frame:
Day 1 up to 39 cycles
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsAlbumin-bound Paclitaxel, Carboplatin + Herceptin
Number with any treatment emergent AE32
Number with any treatment-related AE31
Number with any Grade 3/4 TEAE20
Number with any serious AE5

Adverse events

Collected over Day 1 up to 39 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Albumin-bound Paclitaxel, Carboplatin + Herceptin—5/32 (15.6%)32/32 (100%)
Most frequent serious events
Most frequent serious events
EventAlbumin-bound Paclitaxel, Carboplatin + Herceptin
HypersensitivityImmune system disorders2/32
Febrile neutropeniaBlood and lymphatic system disorders1/32
Supraventricular tachycardiaCardiac disorders1/32
Catheter site infectionInfections and infestations1/32
Confusional statePsychiatric disorders1/32
Most frequent other events
Showing 10 of 78
Most frequent other events
EventAlbumin-bound Paclitaxel, Carboplatin + Herceptin
FatigueGeneral disorders27/32
NauseaGastrointestinal disorders23/32
NeutropeniaBlood and lymphatic system disorders21/32
AnaemiaBlood and lymphatic system disorders20/32
InsomniaPsychiatric disorders17/32
VomitingGastrointestinal disorders16/32
DiarrhoeaGastrointestinal disorders14/32
Peripheral sensory neuropathyNervous system disorders14/32
AlopeciaSkin and subcutaneous tissue disorders14/32
CoughRespiratory, thoracic and mediastinal disorders13/32

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Albumin-bound Paclitaxel, Carboplatin + Herceptin
<=18 years0
Between 18 and 65 years29
>=65 years3
Age, Continuous
Age, Continuous(years)Albumin-bound Paclitaxel, Carboplatin + Herceptin
Median52.0 (29 to 76)
Sex: Female, Male
Sex: Female, Male(Participants)Albumin-bound Paclitaxel, Carboplatin + Herceptin
Female32
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Albumin-bound Paclitaxel, Carboplatin + Herceptin
Black, of African Heritage4
White, Non-Hispanic and Non-Latino26
White, Hispanic or Latino2
Region of Enrollment
Region of Enrollment(participants)Albumin-bound Paclitaxel, Carboplatin + Herceptin
United States32
Menopausal Status
Menopausal Status(participants)Albumin-bound Paclitaxel, Carboplatin + Herceptin
Pre-Menopausal7
Post-Menopausal25
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Albumin-bound Paclitaxel, Carboplatin + Herceptin
0 (Fully Active)19
1 (Restrictive but Ambulatory)12
2 (Ambulatory, but Unable to Work)1
Physician assessment of peripheral neuropathy
Physician assessment of peripheral neuropathy(participants)Albumin-bound Paclitaxel, Carboplatin + Herceptin
Grade 030
Grade 11

6 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • Breastlink Med Group
    Long Beach, California 90806, United States
  • Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center
    Stamford, Connecticut 06902, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Lombardi Cancer Center Georgetown University Hospital
    Washington, District of Columbia 2007, United States
  • Florida Cancer Institute
    Hudson, Florida 34667, United States
  • Gulf Coast Oncology Associates
    Saint Petersburg, Florida 33705, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida 33401, United States
  • Gerogia Cancer Specialist
    Atlanta, Georgia 30341, United States
  • Maine Center for Cancer Medicine and Blood Disorders
    Scarborough, Maine 04074, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • University of Pittsburgh Medical Center Magee Womens Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Southwest Regional Cancer Center
    Austin, Texas 78705, United States
  • Swedish Medical Center Cancer Institute Research
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Conlin AK, Seidman AD, Bach A, Lake D, Dickler M, D'Andrea G, Traina T, Danso M, Brufsky AM, Saleh M, Clawson A, Hudis CA. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2010 Aug 1;10(4):281-7. doi: 10.3816/CBC.2010.n.036. PubMed 20705560 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2004 to primary completion in Oct 2008, 52 months.

Results were first posted in Jul 2013, 4 years 9 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 52 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2004
First posted
Oct 5, 2004
StartActual
Jun 1, 2004
Primary completionActual
Oct 1, 2008
CompletionActual
Oct 1, 2008
Results first posted
Jul 17, 2013
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00093145
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 5, 2004
Start date
Jun 1, 2004
Primary completion
Oct 1, 2008
Completion
Oct 1, 2008
Results posted
Jul 17, 2013
Last update
Nov 25, 2019

Study contacts

Andrew Seidman, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albumin-Bound Paclitaxel · Carboplatin · Trastuzumab

Start the discussion